Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

DOP17: AZD4205, a potent, GI tract-enriched, JAK1-selective inhibitor for treatment of Inflammatory Bowel Disease (IBD)ECCO'19 Copenhagen
Year: 2019
Authors: Mei Wang
JAK inhibitors, Immunology, Lymphocyte, T cell
Files: 1
DOP18: OSM neutralisation in IBD mucosal explant cultures reduces pro-inflammatory cytokine productionECCO'19 Copenhagen
Year: 2019
Authors: Gillian Tannahill
Immunology
Files: 1
DOP20: Drugs that modulate histone acetylation disrupt TGF-β- signalling and reduce collagen I expression in models of stricturing Crohn’s diseaseECCO'19 Copenhagen
Year: 2019
Authors: Amy Lewis
Files: 1
DOP22: UC-related and segment-specific properties of patient-derived colonic organoids.ECCO'19 Copenhagen
Year: 2019
Authors: Kohei Suzuki
Epithelial cell
Files: 1
DOP23: Myenteric plexitis and post-operative recurrence in Crohn’s disease: the role of enteric glial cells and ICAM-1ECCO'19 Copenhagen
Year: 2019
Authors: Catherine Le Berre
Ileo caecal resection, Post operative complications, Post operative medical management, Post-operative IBD, Immunology, Lymphocyte, T cell
Files: 1
DOP24: Intestinal acidification sensed by pH-sensing receptor GPR4 contributes to fibrogenesisECCO'19 Copenhagen
Year: 2019
Authors: Bruce Weder
Fibroblast, Fibrosis
Files: 1
DOP25: Unraveling Vedolizumab mechanism of action in Ulcerative ColitisECCO'19 Copenhagen
Year: 2019
Authors: Marisol Veny
Vedolizumab, Lymphocyte
Files: 1
DOP26: Biological therapy increases NCR+ ILC3 levels in IBD patientsECCO'19 Copenhagen
Year: 2019
Authors: Brecht Creyns
Immunology, Innate lymphoid cell, Lymphocyte
Files: 1
DOP28: Maternal obstetric outcomes in women with IBD compared to the general populationECCO'19 Copenhagen
Year: 2019
Authors: Gillian Lever
IBD in pregnancy
Files: 1
DOP30: Factors associated with life satisfaction in people with Crohn's Disease and Ulcerative Colitis: results from the national 2018 Crohn's and Colitis UK Inflammatory Bowel Disease Quality of Life SurveyECCO'19 Copenhagen
Year: 2019
Authors: Georgina Rowse
Crohn’s disease, Ulcerative colitis, Quality of life (IBDQ), Psychological co-morbidity, Psychological co-morbidity, Coping
Files: 1
DOP31: Development and validation of the IBD-REFER criteria: when should a general practitioner or pediatrician refer a patient for suspected IBD?ECCO'19 Copenhagen
Year: 2019
Authors: Dan Turner
Files: 1
DOP32: Withdrawal of thiopurines in Crohn’s disease treated with scheduled adalimumab maintenance: a prospective randomised clinical trial (DIAMOND2)ECCO'19 Copenhagen
Year: 2019
Authors: Tadakazu Hisamatsu
Adalimumab, Anti-TNF agents, Thiopurines (AZA / MP), Disease activity indices, Mucosal healing
Files: 1
DOP33: Long-term clinical efficacy of ustekinumab in refractory Crohn’s disease : a multi-centre Belgian cohort studyECCO'19 Copenhagen
Year: 2019
Authors: Claire Liefferinckx
Ustekinumab, Real world data
Files: 1
DOP34: Disease activity patterns during the first 5 years after diagnosis in children with ulcerative colitis: a population-based studyECCO'19 Copenhagen
Year: 2019
Authors: Marina Aloi
Montreal Classification, Paediatric
Files: 1
DOP36: Gut microbial variations in patients with quiescent Crohns disease predict subsequent disease flareECCO'19 Copenhagen
Year: 2019
Authors: Yael Haberman
Microbiota, Crohn’s disease, Calprotectin and other faecal biomarkers, CRP and other serum biomarkers, Prognosis, Microbiota
Files: 1
DOP37: Vedolizumab-induced endoscopic remission in anti-TNF exposed and anti-TNF naïve IBD patients: a large single centre experienceECCO'19 Copenhagen
Year: 2019
Authors: Bram Verstockt
colonoscopy, Mucosal healing, Vedolizumab, Mucosal healing, Real world data, Mucosal healing
Files: 1
DOP38: A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel diseaseECCO'19 Copenhagen
Year: 2019
Authors: Bram Verstockt
Mucosal healing, Prognosis, Anti-TNF agents, Vedolizumab
Files: 1
DOP39: Safety of Combination Biologic and Anti-Rejection Therapy Post-Liver Transplantation in Patients with Inflammatory Bowel Disease: London Ontario ExperienceECCO'19 Copenhagen
Year: 2019
Authors: Christopher Ma
Adalimumab, Anti-TNF agents, Golimumab, Infliximab, Ustekinumab, Vedolizumab, Sclerosing Cholangitis, IBD-associated cancer, Clostridium difficile, Colorectal cancer, CMV, IBD and malignancy, Mortality, Real world data, Patient reported outcomes
Files: 1
DOP40: Effectiveness and safety of reference infliximab and biosimilar in Crohn’s disease: a French equivalence studyECCO'19 Copenhagen
Year: 2019
Authors: Antoine Meyer
Anti-TNF agents, Biosimilars, Real world data
Files: 1
DOP41: Efficacy and safety of open-label treatment with tofacitinib 10 mg twice daily in patients with ulcerative colitis with clinical response, but not remission, after 52 weeks of maintenance therapy: Data from the OCTAVE studiesECCO'19 Copenhagen
Year: 2019
Authors: Russell D Cohen
Tofacitinib, JAK inhibitors, Ulcerative colitis
Files: 1